Here's the Reason Grail Stock Outperformed the Market This Week

Grail Stock Surges After Analyst Upgrade

This week, shares of Grail (NASDAQ: GRAL), a company specializing in multi-cancer early detection (MCED) tests, climbed as much as 12.4%. The rally followed a Wall Street analyst’s decision to upgrade the stock from "hold" to "buy," even though the price target was lowered from $110 to $65. Despite the cut, this new target still stands 39% above the previous Friday’s closing price.

Renewed Optimism from Wall Street

Although Grail’s stock has faced challenges this year—particularly after disappointing results from a major trial in the UK, where its Galleri test failed to achieve a statistically significant reduction in late-stage (Stage III-IV) cancer detection—the recent analyst upgrade has sparked renewed interest. The trial was designed to identify cancers earlier, aiming to lower the proportion of late-stage diagnoses in the tested group compared to a control group.

Some experts believe the trial’s inability to meet its main goal may be attributed to the way the study was structured. There is hope that additional follow-up data will demonstrate the effectiveness of the Galleri test, potentially paving the way for FDA approval and insurance reimbursement. The analyst upgrade from TD Cowen reflects this perspective.

Positive Signs for Grail’s Future

Encouragingly, the trial showed a significant increase in early-stage (Stage I-II) cancer detections and a notable reduction in Stage IV diagnoses across a group of 12 particularly deadly cancers, compared to standard care alone.

However, an uptick in Stage III cancer detections meant that the combined reduction in Stage III and IV cases—the trial’s primary endpoint—did not reach statistical significance. As previously discussed by management, there is optimism that six- to twelve-month follow-up results will further support the Galleri test, especially since new cancers may emerge in the control group over time.

Investors should remember that clinical trials often involve significant uncertainty, and decisions should be made based on the balance of probabilities. TD Cowen’s recent upgrade suggests confidence in Grail’s current valuation, a sentiment echoed by many investors this week.

Is Now the Right Time to Invest in Grail?

Before making an investment in Grail, consider this:

Stock Advisor’s Track Record

• If you had invested $1,000 in Netflix when it was recommended on December 17, 2004, your investment would now be worth $494,747.*
• A $1,000 investment in Nvidia after its recommendation on April 15, 2005, would have grown to $1,094,668.*

As of March 21, 2026, Stock Advisor’s average return stands at 911%, far outpacing the S&P 500’s 186%. Don’t miss out on the latest top 10 stock picks, available through Stock Advisor, and become part of a community built for individual investors.

*Returns as of March 21, 2026.